DARE Latest News, Press Relases and Analysis

All

Press Releases

21 days ago - By: Daré Bioscience, Inc.

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic

a month ago - By: Daré Bioscience, Inc.

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

2 months ago - By: Benzinga - Mentions: CHRS CPRT EAT LDOS

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

2 months ago - By: Zacks Investment Research - Mentions: AUNA

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Benzinga - Mentions: TRIB UNH ONMD PAHC ...

12 Health Care Stocks Moving In Thursday's After-Market Session

2 months ago - By: The Motley Fool

Daré Bioscience Posts Narrower Q2 Loss

5 months ago - By: Daré Bioscience, Inc.

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

2 months ago - By: Daré Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Zacks Investment Research - Mentions: IMTX

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: EDIT

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: CCCC

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Daré Bioscience, Inc.

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

3 months ago - By: Zacks Investment Research - Mentions: ARVN

Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Daré Bioscience, Inc.

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

3 months ago - By: Daré Bioscience, Inc.

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

3 months ago - By: Daré Bioscience, Inc.

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

4 months ago - By: Daré Bioscience, Inc.

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

4 months ago - By: Daré Bioscience, Inc.

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

5 months ago - By: Zacks Investment Research - Mentions: BSX

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

6 months ago - By: Daré Bioscience, Inc.

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

6 months ago - By: Zacks Investment Research - Mentions: ACHC

Acadia Healthcare (ACHC) Beats Q1 Earnings Estimates

6 months ago - By: Zacks Investment Research - Mentions: CTKB

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: Daré Bioscience, Inc.

DARE BIOSCIENCE INC (DARE) Stock News

DARE Latest News, Press Relases and Analysis

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

12 Health Care Stocks Moving In Thursday's After-Market Session

Daré Bioscience Posts Narrower Q2 Loss

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Acadia Healthcare (ACHC) Beats Q1 Earnings Estimates

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025